Anne Beaufour is a French billionaire businesswoman and a core heir to the Ipsen Pharmaceutical fortune, one of France's leading biopharmaceutical companies. Born in Neuilly-sur-Seine, France, in 1963, her life has been intrinsically linked to the medical world since her grandfather, Dr. Henri Beaufour, founded the Beaufour Laboratories in 1929.

Her father, Albert Beaufour, continued the legacy, expanding the company significantly during the mid-20th century. Anne pursued an academic path, earning a degree in Geology from the University of Paris-Sud, an unusual choice that demonstrates an independent intellectual curiosity outside the core family business. However, upon the death of her father in 2000, she and her brother, Henri Beaufour, became the primary stewards of the family’s wealth, inheriting a controlling stake in the biopharma giant.

Anne Beaufour’s career is defined by her role as a major shareholder and board member responsible for the long-term governance of Ipsen. The company, which has been family-owned for nearly a century, specializes in developing and commercializing drugs in high-value therapeutic areas like Oncology, Rare Diseases, and Neuroscience. When her father passed away in 2000, the family’s 76% capital stake was divided, and Anne, along with her brother Henri, consolidated their control, retaining the decisive influence over the publicly traded company.

Anne sits on the Board of Directors of both Ipsen and Mayroy, the private holding company that controls the family's stake. Her role is primarily strategic and fiduciary, ensuring that the company maintains its independence and its commitment to long-term research and development, a critical element for success in the biopharmaceutical sector. This responsible stewardship of a multi-billion euro legacy company in a vital sector of global healthcare is the source of her wealth and influence.

Anne Beaufour’s social impact is channeled through Fondation Ipsen, the corporate foundation dedicated to advancing medical research and science. The foundation plays a crucial role in promoting scientific understanding and knowledge transfer in the specialized fields where Ipsen operates (neuroscience, endocrinology, oncology).

The family's commitment to developing and marketing essential medicines globally (registered in 88 countries) is the most profound form of social contribution, directly impacting the lives of patients suffering from cancer, rare diseases, and neuro-endocrine tumors. As a quiet French heiress, her personal charitable endeavors are discreet, reflecting the preference for institutional, research-driven social contributions typical of European pharmaceutical dynasties.

Anne Beaufour maintains the refined, highly discreet style of the French business aristocracy. Her attire is likely classic, high-end French designer wear—elegant, tailored, and sophisticated, avoiding the ephemeral trends of the fashion world. Her aesthetic is one of quiet, inherited prestige and intellectual reserve.

Her lifestyle is centered in France, characterized by the privacy afforded by multi-billion euro wealth. As a woman deeply entrenched in the governance of a major biopharmaceutical company, her focus is on strategic stability and family continuity. Her luxury is the security of generational wealth tied to a critical, long-term industry, allowing her to live a life of high culture and private, meaningful engagement.